Brokers Offer Predictions for ImageneBio FY2026 Earnings

ImageneBio, Inc. (NASDAQ:IMA – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of ImageneBio in a report issued on Friday, November 13th. HC Wainwright analyst A. He expects that the company will earn ($3.55) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for ImageneBio’s Q4 2026 earnings at ($1.07) EPS, Q1 2027 earnings at ($1.19) EPS, Q2 2027 earnings at ($1.34) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.69) EPS, FY2027 earnings at ($5.73) EPS, FY2028 earnings at ($5.35) EPS, FY2029 earnings at ($5.03) EPS and FY2030 earnings at ($4.95) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research note on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.00.

Check Out Our Latest Analysis on ImageneBio

ImageneBio Stock Performance

NASDAQ:IMA opened at $3.20 on Tuesday. The stock has a 50-day simple moving average of $4.36 and a two-hundred day simple moving average of $5.47. ImageneBio has a 52-week low of $3.13 and a 52-week high of $8.25. The firm has a market capitalization of $36.32 million, a PE ratio of -0.70 and a beta of 0.83.

ImageneBio (NASDAQ:IMA – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.08).

Institutional Trading of ImageneBio

A number of hedge funds and other institutional investors have recently modified their holdings of IMA. Trails Edge Capital Partners LP purchased a new position in shares of ImageneBio during the 2nd quarter valued at $1,663,824. Blue Owl Capital Holdings LP purchased a new stake in ImageneBio in the 2nd quarter worth $5,414,000. Cable Car Capital LP purchased a new stake in ImageneBio in the 2nd quarter worth $4,611,000. BlackRock Inc. purchased a new stake in ImageneBio in the 2nd quarter worth $797,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of ImageneBio in the second quarter valued at about $539,044,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

Key ImageneBio News

Investors following IMA have been watching these news items:

  • Positive Sentiment: A recent report says ImageneBio’s third-quarter loss narrowed as its clinical trials advanced, offering a favorable update on financial performance and pipeline progress. ImageneBio stock: Q3 loss narrows as clinical trials advance
  • Positive Sentiment: HC Wainwright maintained a Strong-Buy rating, a supportive analyst view, while issuing earnings estimates across 2026–2030. ImageneBio analyst coverage
  • Negative Sentiment: The estimates underscore substantial ongoing losses: HC Wainwright forecasts a loss of $3.55 per share in FY2026 and $5.73 in FY2027, versus the cited current-year consensus loss of $3.47. Its quarterly estimates also project losses increasing through 2027, which could weigh on sentiment about funding needs and the path to profitability.

ImageneBio Company Profile

(Get Free Report)

ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases.

Further Reading

Earnings History and Estimates for ImageneBio (NASDAQ:IMA)

Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.